Acetylcholinesterase Inhibitors

Acetylcholinesterase (AChE) inhibitors are a class of drugs commonly used for the treatment of Alzheimer's Disease (AD) and other forms of dementia. AChE inhibitors work by blocking the enzyme AChE, which breaks down the neurotransmitter acetylcholine. By blocking the enzyme, AChE inhibitors help increase concentrations of the neurotransmitter, thereby improving cognitive function and reducing the effects of memory loss associated with Alzheimer's Disease. The four main types of AChE inhibitors used in the treatment of AD and other dementia-related disorders are donepezil, rivastigmine, galantamine, and tacrine. Donepezil is the most commonly-prescribed AChE inhibitor due to its wide safety profile and relatively long duration of action. However, each of the four drugs have their own unique set of side effects and potential interactions with other medications, so it is important for patients to discuss all available options with their physician. Common side effects associated with AChE inhibitors include headaches, nausea, fatigue, diarrhea, dizziness, and weight loss, while more serious side effects may include an increased risk of intestinal and urinary tract infections, as well as an increased risk of stroke or heart attack. It is therefore important to discuss any risk factors or underlying health conditions with your physician before starting an AChE inhibitor medication. Overall, AChE inhibitors have been found to be effective in improving cognitive function and memory in AD and other forms of dementia, though the exact mechanism behind their effects is still largely unknown. While the drugs may be associated with a range of side effects, the potential benefits in terms of improved cognitive function often far outweigh the risks for dementia patients.